Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Try, Try Again: Bain And Cinven File Fresh Bid For Stada

Executive Summary

Stada is likely to approve a second takeover bid from equity groups Bain and Cinven soon, at a new price of €66.25 per share; an offer cleared by Germany's stock market authorities despite a ban in the country on repeat acquisition bids within 12 months.

You may also be interested in...

What Now For Lonely Stada? Bain & Cinven Takeover Bid Collapses

In a surprising twist, Stada investors have not rallied behind a €5.3bn takeover bid from equity groups Bain and Cinven; analysts are baffled as to why the deal didn’t win enough support and what Stada's shareholders are hoping for now.

Acquired Stada To Act As 'Core' For Future Bain and Cinven Bolt-Ons

Cinven and Bain seem likely to use German generics maker Stada as a nucleus around which to add smaller acquisitions, mostly in Europe, for an eventual exit by the private equity firms.

Femtech Presents Enticing Market Opportunity

A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts